TOPplus‐IgAN 2013.

Trial name or title	Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced‐stage IgA Nephropathy (TOPplus‐IgAN)
Methods	Parallel RCT
Participants	Setting: single centre Country: China Biopsy‐proven primary IgAN; aged 18 to 70 years; elevated SCr and < 3.0 mg/dL Number: 122 participants planned Mean age ± SD (years): not yet available Sex (M/F): not yet available Exclusion criteria: DM; contraindications for the treatment of prednisone and/or CPA, any treatment with steroids or immunosuppressive drugs prior to this study, acute deterioration of renal function(including those of glomerular origin)
Interventions	Treatment group 1 Prednisone: 0.5 mg/kg/day for 6 months CPA (IV): 1 g/ month for 6 months Treatment group 2 Prednisone: 0.5 mg/kg/day for 6 months Co‐interventions Supportive care, including ACEi or ARB and BP control
Outcomes	Changes of kidney function or death Changes of proteinuria
Starting date	December 2012
Contact information	Principal Investigator: Wei Shi. Guangdong General Hospital
Notes	Study completion: December 2019 No study results available